This review will discuss the pathophysiology of NMIBC, highlighting the major factors influencing tumor progression within its microenvironment, the role of PD-L1 and CTLA-4 in UBC, and current clinical trials targeting these checkpoints. This evidence concerns the gene CTLA4 and neoplasm.